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Chronic ingestion of high concentrations of hexavalent chro-
mium [Cr(VI)] in drinking water induces intestinal tumors in
mice. To investigate the mode of action (MOA) underlying these
tumors, a 90-day drinking water study was conducted using
similar exposure conditions as in a previous cancer bioassay, as
well as lower (heretofore unexamined) drinking water concen-
trations. Tissue samples were collected in mice exposed for 7 or 90
days and subjected to histopathological, biochemical, toxicoge-
nomic, and toxicokinetic analyses. Described herein are the results
of toxicokinetic, biochemical, and pathological ﬁndings. Following
90 days of exposure to 0.3–520 mg/l of sodium dichromate
dihydrate (SDD), total chromium concentrations in the duo-
denum were signiﬁcantly elevated at ‡ 14 mg/l. At these
concentrations, signiﬁcant decreases in the reduced-to-oxidized
glutathione ratio (GSH/GSSG) were observed. Beginning at
60 mg/l, intestinal lesions were observed including villous
cytoplasmic vacuolization. Atrophy, apoptosis, and crypt hyper-
plasia were evident at ‡ 170 mg/l. Protein carbonyls were elevated
at concentrations ‡ 4 mg/l SDD, whereas oxidative DNA damage,
as assessed by 8-hydroxydeoxyguanosine, was not increased in any
treatment group. Signiﬁcant decreases in the GSH/GSSG ratio
and similar histopathological lesions as observed in the duodenum
were also observed in the jejunum following 90 days of exposure.
Cytokine levels (e.g., interleukin-1b) were generally depressed or
unaltered at the termination of the study. Overall, the data suggest
that Cr(VI) in drinking water can induce oxidative stress, villous
cytotoxicity, and crypt hyperplasia in the mouse intestine and may
underlie the MOA of intestinal carcinogenesis in mice.
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Until recently, there was inadequate information to assess the
oral carcinogenicity of hexavalent chromium [Cr(VI)] (In-
ternational Agency for Research on Cancer, 1990; U.S. EPA,
1991, 1998); however, a 2-year cancer bioassay conducted by
the National Toxicology Program (NTP) reported that admin-
istration of Cr(VI) in drinking water (in the form of sodium
dichromate dihydrate [SDD]) induced tumors in the small
intestines of mice at   57 mg/l SDD (  20 mg/l Cr(VI)) and in
the oral cavities of rats at   172 mg/l SDD (  60 mg/l Cr(VI))
(NTP, 2008; Stout et al.,2 0 0 9 ). Because low levels of Cr(VI)
are prevalent in groundwater in certain geographical areas (Oze
et al., 2007), wide-spread impact to some drinking water
supplies has occurred. For example, approximately one third of
California drinking water supplies contain low levels of
Cr(VI)—mostly ranging from 0.001 to 0.005 mg/l (California
Department of Health Services, 2009); thus, the effects of
Cr(VI) at low concentrations is of interest. Notably, the
concentrations inducing cancer in rodents are orders of
magnitude greater than typical drinking water exposures
(Thompson et al., 2011).
In the NTP 2-year cancer bioassay (NTP, 2008), diffuse
intestinal epithelial hyperplasia was observed in the small
intestineofmiceatallconcentrationsexamined(NTP,2008)and
at   62.5 mg/l SDD in an earlier 90-day study (NTP, 2007). In
stark contrast to mice, neither diffuse hyperplasia nor tumors
were reported in the rat small intestine at any of the drinking
water concentrations tested (NTP, 2007, 2008). The non-
neoplastic intestinal lesions in the mouse were characterized by
the NTP investigators as ‘‘regenerative hyperplasia secondary to
previous epithelial cell injury’’ (NTP, 2008) and suggest that the
tumors may have been caused by prolonged tissue injury and
proliferative pressure on crypt cells (Thompson et al., 2011).
Despiteevidencethatchromiumcanbegenotoxicandmutagenic
(McCarroll et al., 2010; Nickens et al., 2010; O’Brien et al.,
2003), there are limited data to evaluate the mode of action
(MOA)ofCr(VI)inthesmallintestine.Thus,theMOAforsmall
intestinal tumors at high concentration exposures is uncertain,
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doses in rodents are of relevance for humans exposed at levels
that are typically orders of magnitude lower.
Using the NTP Cr(VI) study data (NTP, 2007, 2008) and the
MOA framework in the U.S. EPA Guidelines for Carcinogen
Risk Assessment (U.S. EPA, 2005), we hypothesized a plausi-
ble MOA for the mouse intestinal tumors that includes the
following key events: saturation of the reductive capacity of
the upper gastrointestinal (GI) tract, absorption of Cr(VI) into
the intestinal epithelium, oxidative stress and inﬂammation,
cell proliferation, direct and/or indirect DNA modiﬁcation, and
mutagenesis (Thompson et al., 2011). Although available data
generally support the plausibility of these key events, the
following key data gaps were identiﬁed: (1) species-speciﬁc
measuresofreductive capacityofthe upper GItract,(2) measures
of intestinal oxidative stress and inﬂammation, (3) a molecular
basis for the cause of cell proliferation, (4) measures of target
tissue DNA modiﬁcation (e.g., Cr-mediated damage, oxidative
damage, epigenetic changes—all of which have been shown to
occur in other tissues and by other routes of exposure), and
(5) whether Cr(VI) exposure results in measurable mutations
(e.g., p53 and ras) in target tissues within 90 days of exposure.
These data gaps are being addressed through a series of Cr(VI)
MOA studies.
As part of this project, a 90-day drinking water study was
designed to acquire the biochemical, genomic, and species-
speciﬁc toxicokinetic data needed to extrapolate among species
and from the high doses that caused tumors in rodents to envi-
ronmentally relevant exposures in humans. The study design is
similartothatofthe90-dayNTPstudy(NTP,2007);however,the
drinking water concentrations employed were based on those in
the 2-year bioassay (NTP, 2008) and included two additional
lowerdrinkingwaterconcentrations.Inaddition,thepresentstudy
includes analyses of biochemical and genomic changes in the
targettissuesafter7and90daysofexposure.Herein,wereportthe
results of the in-life portion of the 90-day mouse study as well as
descriptions of the histopathological ﬁndings, biochemical ana-
lysesrelatedtooxidativestatus,andthechromiumcontentintarget
tissues. In addition to informing the MOA, these data will be used
to provide phenotypic anchoring for the toxicogenomic results
once completed. Toxicogenomic, in vivo mutagenicity, and
toxicokinetic modelingresults, as well as ﬁndings from a compan-
ion90-daydrinkingwaterstudyinrats,willbepublishedseparately
upon completion of those studies.
MATERIALS AND METHODS
Test substance. SDD (99.95% pure; CAS 7789-12-0) was obtained from
Sigma-Aldrich Inc. (Milwaukee, WI) and was stored at room temperature and
protected from light. The dose formulations were prepared at concentrations of
0.3, 4, 14, 60, 170, and 520 mg/l SDD in tap water, which is equivalent to
0.1, 1.4, 4.9, 20.9, 59.3, and 181 mg/l Cr(VI) (The Cr(VI) concentration is
equivalent to approximately 35% of the SDD concentration.). On the ﬁrst, third,
ﬁfth, and seventh (ﬁnal) batch preparations, samples were collected and shipped
to Brooks Rand Laboratories (Seattle, WA) for analysis of Cr(VI) content. The
ﬁrst batch was also analyzed for total chromium. Samples were prepared and
analyzed in accordance with EPA Method SW-7196A and modiﬁed (Standard
Operating Procedures, SOP BR-0085) to conﬁrm the Cr(VI) concentrations of
the administered drinking water. In Method 7196A, Cr(VI) is complexed with
diphenylcarbazide in an acidic solution and measured colorimetrically at an
absorbance of 540 nm. Batches found to differ from the target concentration
by ± 10% were not used. Prior to use, dose formulations of SDD were stored
in sealed Nalgene carboys at room temperature protected from light. SDD
has been shown to be stable for 42 days in dosed water formulations at a
concentration of 41.8 mg/l when stored under these conditions (NTP, 2008).
Animals and husbandry. The in-life studies were conducted at Southern
Research Institute (Birmingham, AL), the same research facility at which both
the NTP 13-week study and the NTP 2-year bioassay (NTP, 2007, 2008) were
conducted. The water bottles, sipper tubes, cage size and type, number of
animals per cage, bedding, environmental conditions, and food were the
same as in the NTP studies. Female B6C3F1 mice were obtained from
Charles River (Raleigh, NC). The mice were approximately 4–5 weeks of
age when they arrived and were allowed to acclimate for approximately
2 weeks. At the start of the study, the mice were approximately 6–7 weeks
of age and weighed between 13.3 and 22.9 g. Irradiated NTP-2000 Wafers
(Zeigler Bros., Gardners, PA) were provided ad libitum during the pre-study
and study periods. Water (dosed or control) was supplied in amber glass
water bottles. Teﬂon-lined lids with stainless steel, double-balled sipper
tubes were used. Water bottles were changed twice weekly, or as needed.
Before the start of the study, samples of tap water from the animal facility
were analyzed, and no known contaminants were present that would be
expected to interfere with or affect the outcome of the study.
The animals were group-housed (5 per cage) in solid bottom polycarbonate
cages on a stainless steel rack in a room maintained at a temperature of
68.4 F–78.0 F and a relative humidity of 24.7–76.5%. Excursions outside
the desired temperature (69 F–75 F) and humidity (35–65%) ranges were
brief in duration and did not adversely affect the health of the animals or
outcome of the study. Fluorescent lighting provided illumination approx-
imately 12 h per day. Irradiated hardwood bedding chips (Sani Chips;
P.J. Murphy Forest Products Corp., Montville, NJ) were used as bedding
material. No known contaminants were present in the bedding that would
have been expected to interfere with or affect the outcome of the study. Cage
size and animal care conformed to the guidelines of the Guide for the Care
and Use of Laboratory Animals, the U.S. Department of Agriculture through
the Animal Welfare Act (Public Law 99-198) and to the applicable SOPs
of Southern Research.
Study design. Because male and female mice responded similarly to
Cr(VI) in terms of effects in the alimentary canal, only female mice were used
in this study (The design of this study was informed by the Toxicology
Excellence for Risk Assessment Expert Panel overseeing the Cr(VI) MOA
Research Program, who recommended that multiple sexes were not neces-
sary for this study. The panel report is available at http://www.tera.org/Peer/
Chromium/Chromium.htm.). Mice were assigned to their respective dose
groups using a computerized randomization procedure designed to yield
comparable group mean body weights. The body weights required for
randomization were determined the week before the treatment began. After
randomization, mice were assigned to treatment groups as indicated in Table 1
and were provided with food and drinking water ad libitum until study
termination at days 8 or 91 (Table 1). Water and food consumption were
measured weekly for each cage of animals throughout the study, and values
were reported as an average consumption (milliliters/animal per day or grams/
animal per day, respectively). Each animal was weighed the week before
treatment began (for randomization), on day 1, weekly thereafter, and prior to
scheduled euthanasia. All animals were observed at least twice daily during the
pre-study and study periods for signs of mortality and moribundity. Each
animal was removed from its cage and examined for clinical signs of toxicity
on day 1 and weekly thereafter.
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pathologic examination (i.e., those in the toxicology and histopathology
groups) were euthanized by CO2 asphyxiation and subjected to a complete
gross examination at the time of necropsy. The postmortem examination of
each mouse included, but was not limited to, examination of the external
surfaces of the body, all oriﬁces of the body, and the cranial, thoracic,
abdominal, and pelvic cavities and their contents. Based on ﬁndings of the
NTP (2008) bioassay , the oral cavity, duodenum, jejunum, and any gross
lesions were collected from each mouse and saved in 10% neutral-buffered
formalin for histopathologic evaluation. Fixed tissues were trimmed, pro-
cessed, and sectioned to approximately 5 lm. The tissue sections were
mounted on glass slides and stained with hematoxylin and eosin for micro-
scopic examination. All slides were submitted to a veterinary pathologist for
evaluation and diagnosis. Tissues were diagnosed and categorized using
standardized nomenclature with lesions ranked for severity for comparison
among groups. Half of the mice designated for macroscopic and micro-
scopic pathology evaluation were also used for collection of samples for
evaluation of iron status. One bone marrow smear (stained with Prussian
blue) was prepared from 5 mice per group.
GSH and GSSG analyses. GSH and GSSG were measured in plasma, as
well as in oral epithelial scrapings and in duodenal and jejunal epithelial
scrapings from 5 animals per group on days 8 and 91 and in ileal epithelial
scrapings from 5 animals per group on day 91. For collection of blood samples,
each mouse was anesthetized with ketamine/xylazine (87 mg ketamine/kg;
13.4 mg xylazine/kg) injected intraperitoneally or with CO2/O2 by inhalation,
and blood samples were collected from the retro-orbital sinus into tubes
containing heparin as anticoagulant. Samples were gently mixed by inversion
and placed on ice. Samples were centrifuged at approximately 4 C for 5 min for
separation of plasma. Plasma was collected and mixed in a 1:1 ratio with
23 redox quenching buffer (RQB), to yield ﬁnal concentrations of 20mM
HCl, 5mM diethylenetriamine pentaacetic acid, and 1mM 1,10-phenanthroline.
The 23 RQB also contained 5% ultrapure grade trichloroacetic acid. Samples
were snap frozen and stored at  80 C until analysis. Immediately following
blood collection, each mouse was euthanized using CO2. Samples of oral,
duodenal, jejunal (proximal 6 cm), and ileal (proximal 6 cm; day 91 only)
epithelia were collected, immediately placed into tubes containing 0.5 ml
23 RQB on ice, and incubated for approximately 10–15 min to allow
penetration of the buffer into the tissues. The samples were then snap frozen
in liquid nitrogen and stored at  80 C until analysis. GSH and GSSG
were determined ﬂuorometrically using the o-phthalaldehyde procedure as
previously described (Senft et al., 2000). The calculation for redox potential
(DE) is described in detail elsewhere (Dalton et al.,2 0 0 4 ) and is as follows:
DE ¼  240 mV   (61.5 mV/2) 3 log([GSH]
2/[GSSG]).
Cytokine and chemokine analyses. One sample of oral cavity and one
sample of duodenum from each animal were snap frozen and stored at  80 C
until homogenization. Homogenization buffer solution was prepared by
dissolving phenylmethanesulfonylﬂuoride (PMSF) in 2-propanol. The solution
was vortexed ~30 s and set aside. Tris was weighed and transferred to a
beaker and deionized (DI) water was added. The pH was adjusted to 7.5 with
1 N NaOH while stirring. NaCl, Tween 20, and 1 ml of the PMSF/2-propanol
solution were added to the Tris/DI water solution. Protease Inhibitor Cocktail I
[containing 4-(2-aminoethyl) benzenesulfonyl ﬂuoride hydrochloride (AEBSF),
EDTA, bestatin, E-64, leupeptin, and aprotinin] was reconstituted by the
addition of 10 ml of DI water, vortexed ~30 s, and added to the Tris/DI water/
NaCl/Tween 20/PMSF solution. The ﬁnal solution was stirred ~7 min to
ensure uniform mixture. The ﬁnal concentrations of the constituents in the
homogenization buffer were 20 mmol/l Tris, 150 mmol/l NaCl, 1% 2-propanol,
0.174 mg/ml PMSF, 0.05% Tween 20, 2mM AEBSF, 1mM EDTA, 130lM
bestatin, 14lM E-64, 1lM leupeptin, and 0.3lM aprotinin. Tissues were then
homogenized in 0.3 ml using an Omni THQ homogenizer (Omni International,
Kennesaw, GA) and a disposable hard tissue tip. After homogenization,
samples were snap frozen and stored at  80 C until assayed. For serum
collection, each mouse was anesthetized with CO2/O2, and blood samples were
collected from the retro-orbital sinus into serum separator tubes containing no
anticoagulant. The contents of the tubes were centrifuged to separate serum.
The tissue and sera samples were analyzed for 22 cytokines/chemokines via
a Milliplex Mouse Cytokine kit (Millipore, Billerica, MA) on a Luminex 200
(Austin, TX). The cytokines/chemokines included are listed in Supplementary
Table S1. Cytokine levels were normalized to protein content.
Protein carbonyl analyses. Duodenal tissues were homogenized in a PBS
buffer containing a cocktail of protease inhibitors (Millipore) and 0.005% ﬁnal
volume of butylated hydroxytoluene (Sigma, St Louis, MO) to prevent
oxidation. Homogenization was completed using 0.5 or 1 ml (depending on
tissue weight) of the buffer described above and an Omni THQ homogenizer
and a disposable hard tissue tip. After homogenization, an ammonium sulfate
precipitation was completed to remove any residual nucleic acids from the
protein. The protein pellet was resuspended in the same buffer and a Micro-
BCA assay (Pierce, Rockford, IL) was completed to determine the protein
concentration. Samples were then stored at  80 C. Protein carbonyls were
measured via OxiSelect Protein Carbonyl ELISA Kit (Cell Biolabs, San Diego,
CA) per the manufacturer’s instructions.
TABLE 1










Mutation analyses Toxicokinetic analyses
Day 8 Day 91 Day 8 Day 91 Day 8 Day 91 Day 91/92 Day 92
0 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
0.3 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
4 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
14 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
60 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
170 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
520 5 F 10 F 10 F 20 F 10 F 10 F 10 F 5 F
Note. F, female mice.
aSome animals were treated for 90 or 91 days and sacriﬁced thereafter to accommodate study size.
60 THOMPSON ET AL.8-hydroxydeoxyguanosine analyses. DNA was extracted from the oral
cavity and duodenum tissue samples using Gentra PureGene Tissue Kits
(Qiagen, Valencia, CA). To each vial of tissue sample, 300 ll of cell lysis
buffer (included in the Qiagen kit) was added, and the tissues were
homogenized using an Omni THQ homogenizer and a disposable hard tissue
tip. DNA was then extracted following the manufacturer’s instructions.
Genomic DNA samples were rehydrated with 50 ll of DNA hydration solution
(included in the Qiagen kit), and concentrations were determined using the
PicoGreen kit (Invitrogen, Carlsbad, CA) and a Bio-Rad Versaﬂuor ﬂuorimeter
(Hercules, CA). 8-Hydroxydeoxyguanosine (8-OHdG) was measured via
OxiSelect Oxidative DNA Damage ELISA Kit (Cell Biolabs) per the
manufacturer’s instructions.
Iron status. Iron status was evaluated in half of the mice designated for
macroscopic and microscopic pathological evaluation. On day 91, ﬁve mice per
group were anesthetized using CO2/O2, and blood samples (~0.4 ml) were
collected from the retro-orbital sinus into tubes containing no anticoagulant.
The contents of the tubes were centrifuged to separate serum. One aliquot of
serum was used for measurement of serum iron and another was snap frozen
and stored at approximately  80 C. Serum iron was measured using the Cobas
c501 Clinical Chemistry Analyzer (Version 04-02; Roche Diagnostics,
Indianapolis, IN). Blood ferritin and transferrin were measured by commercial
Ferritin (Mouse) ELISA and Transferrin (Mouse) ELISA kits purchased from
ALPCO (Salem, NH).
Measurement of total chromium in GI tissues. Samples of the
duodenum, jejunum, ileum, glandular stomach, and oral cavity were collected
for evaluation of total chromium (Cr) content from mice exposed for 90 days.
Five mice per group were anesthetized using CO2, and tissues were removed,
ﬂushed of contents, snap frozen, and stored at approximately  80 C. Samples
were shipped frozen to Brooks Rand Laboratories where samples were thawed
lightly homogenized and approximately 100 mg of tissue was digested in
nitric acid in a controlled microwave digestion program. Samples were then
brought to a ﬁnal volume of 8 ml with DI water. Analysis was performed
using EPA Draft Method 1638 (modiﬁed) using inductively coupled plasma-
mass spectrometry (ICP-MS) with Dynamic Reaction Cell (DRC) technology.
Digested sample were analyzed utilizing internal standardization with
rhodium (Rh). This method incorporates ionization of the sample in an
inductively coupled RF plasma, with detection of the resulting ions by mass
spectrometer on the basis of their mass-to-charge ratio. The limit of detection
was 0.02 lgC r / gt i s s u e .
Additional analyses relevant to the MOA study. Additional blood and
tissue samples were collected for gene expression analyses, mutation analyses,
analysis of chromium levels in genomic DNA, and toxicokinetic analyses
(Table 1). The results from these studies will be described in future publications
when the analyses are completed. The histopathological and biochemical
ﬁndings described in the present publication are expected to provide
a phenotypic anchor to the gene expression analyses.
Data management and statistical evaluation. Provantis (Version 7;
Instem Life Sciences Systems Ltd., Staffordshire, UK) was used for the direct
online capture of most in-life and pathology data. In addition, Provantis
interfaced with the Cobas c501 Clinical Chemistry Analyzer (Version 04-02;
Roche Diagnostics) for capture of serum iron data. Environmental monitoring
of animal rooms (i.e., temperature/humidity and light/dark cycles) was
performed using the Edstrom Watchdog System (Version 5.13; Edstrom
Industries Inc., Waterford, WI). The remainder of the data was collected
manually.
For consistency with NTP practices, biochemical and clinical endpoints
were ﬁrst tested for dose-related trends using Jonckheere’s test (Jonckheere,
1954). Biochemical data sets with a signiﬁcant trend were then analyzed by
Williams’ (parametric) or Shirley’s tests (nonparametric) (Shirley, 1977),
whereas Dunnett’s (parametric) or Dunn’s (nonparametric) tests were run if
there was not a monotone trend. Water consumption and bodyweight data
were analyzed by one-way ANOVA followed by Dunnett’s tests. Food intake
was found to be non-normally distributed and was analyzed by Kruskall-
Wallis test, followed by Wilcoxon-Mann-Whitney test with Bonferroni
adjustment. Statistical packages used included R (http://www.R-project.org),
Prism 5 for Mac (GraphPad Software, San Diego, CA, www.graphpad.com)
and Provantis. Microscopic lesion data were analyzed by Fisher’s exact test
(one-sided) using Prism 5 for Mac.
RESULTS
Gross and Microscopic Findings
General health. Administration of Cr(VI) as SDD in
drinking water for 90 days had no effect on the survival of
the mice nor were there any clinical signs of treatment-related
toxicity in this study. There was a signiﬁcant decrease in
bodyweight at 520 mg/l SDD, which was ﬁrst evident on
day 15 and continued throughout the study. The maximum
differences between mean body weights of mice in the 170 and
520 mg/l SDD dose groups versus those in the vehicle control
group were < 5% and < 10%, respectively. Therefore, the
observed deﬁcits in bodyweight gain were deemed to be
minimal (170 mg/l) or mild (520 mg/l) and were considered to
be of no toxicological or biological signiﬁcance. Data on
water consumption suggest the weight difference reported
herein might be related to changes in water intake. A summary
of bodyweight and water consumption data is presented in
Supplementary materials (Supplementary Fig. S1 and Table S2).
SDD had no effect on food consumption at any dose level (data
not shown), whereas water consumption in the 170 and 520 mg/l
SDD dose groups were signiﬁcantly lower than in mice in the
vehicle control group. Based on the bodyweight and water
consumption values, average daily ingested SDD and Cr(VI)
levels over the duration of the study were estimated (Supple-
mentary Table S2). The reductions in bodyweight were
consistent with observations in the NTP (2007) study, where
no change was reported at 62 mg/l SDD but small decreases were
observed at doses   125 mg/l SDD. Similarly, the NTP (2007)
reported reductions in water intake at doses   125 mg/l SDD.
Pathology on day 8. No treatment-related gross lesions were
observed in the oral cavity or small intestine on day 8 nor were
any microscopic lesions observed in the oral cavity. In the
duodenum, cytoplasmic vacuolization of the villous epithelium
was observed at   170 mg/l SDD. At 520 mg/l SDD, villous
atrophy and crypt cell hyperplasia were also evident in the
duodenum (Fig. 1A). In the jejunum, cytoplasmic vacuolization
of the villous epithelium was observed at   170 mg/l SDD
(Fig. 1B); however, the effects were milder and less prevalent than
in the duodenum (Table 2). There were no apparent adverse effects
in the small intestine at   60 mg/l SDD.
Pathology on day 91. Consistent with ﬁndings from
a previous 13-week drinking water study (NTP, 2007), no
treatment-related gross lesions were observed after 90 days of
exposure to SDD. There were no microscopic lesions observed
in the oral cavity. In the duodenum, 50% of the mice exhibited
MODE OF ACTION OF ORAL TOXICITY OF Cr(VI) 61FIG. 1. Pathology. (A) Duodenum of mouse exposed to 520 mg/l SDD for 8 days: with villous atrophy, blunting and fusion, and crypt epithelial hyperplasia.
(B) Jejunum of mouse exposed to 170 mg/l SDD for 8 days: with cytoplasmic vacuolization of the villous epithelium (arrows). (C) Duodenum of mouse exposed to
520 mg/l SDD for 90 days: with villous atrophy, blunting and fusion (arrow), and crypt epithelial hyperplasia. (D) Duodenum of mouse exposed to 520 mg/l SDD
for 90 days: with crypt epithelial hyperplasia. (E) Duodenum of mouse exposed to 520 mg/l SDD for 90 days: with histiocytic cellular inﬁltration of the villous
lamina propria (arrows) and cytoplasmic vacuolization of the villous epithelium. (F) Jejunum of mouse exposed to 170 mg/l SDD for 90 days: with a multinucleate
syncytium in the villous lamina propria (arrow). (G) Duodenum of mouse exposed to 520 mg/l SDD for 90 days: with apoptosis in the lamina propria (arrow) and
cytoplasmic vacuolization of the villous epithelium. (H) Duodenum of a control mouse on day 91.
62 THOMPSON ET AL.cytoplasmic vacuolization of the villous epithelium at a con-
centration of 60 mg/l SDD (Table 2). At 170 mg/l SDD, all of
the mice exhibited villous cytoplasmic vacuolization in the
duodenum and 90% exhibited of crypt cell hyperplasia. There
were also signs of villous atrophy (1/10) and apoptosis (3/10) at
170 mg/l SDD. At 520 mg/l SDD, 70% of the mice exhibited
villous cytoplasmic vacuolization, 90% exhibited crypt cell
hyperplasia, 50% exhibited villous atrophy, and 40% exhibited
apoptosis. Histiocytic cellular inﬁltration into the villous lamina
propria was observed in the duodenum of all mice at   170 mg/l
SDD. Multinucleated syncytia (fused cells) in the villous lamina
propria were present in 40% of the mice exposed to 520 mg/l
SDD.Histopathological ﬁndingintheduodenum issummarized
in Figure 1C–E, 1G and 1H).
In the jejunum, 40% of the mice exhibited cytoplasmic
vacuolizationofthevillousepitheliumat60mg/lSDD(Table2).
At170mg/lSDD,80%ofthemiceexhibitedvillouscytoplasmic
vacuolization, 50% exhibited crypt cell hyperplasia, and 30%
exhibited villous atrophy. At 520 mg/l SDD, 50% of the mice
exhibited villous cytoplasmic vacuolization, 70% exhibited
crypt cell hyperplasia, 40% exhibited villous atrophy, and 2/10
miceexhibited apoptosis.Histiocytic cellularinﬁltrationintothe
villous lamina propria was also observed in the jejunum of
90% and 100% of mice exposed to 170 and 520 mg/l SDD,
TABLE 2
Summary of Histopathology in the Mouse Duodenum and Jejunum
Pathology
SDD (mg/l)
0 0.3 4 14 60 170 520
Day 8
Duodenum
Villous cytoplasmic vacuolization — — — — — þ (3/5) þ (5/5)
a
Villous atrophy — — — — — — þ (3/5)
Crypt cell hyperplasia — — — — — — þ (3/5)
Jejunum — — — —
Villous cytoplasmic vacuolization — — — — — þ (1/5) þ (1/5)
Villous atrophy — — — — — — —
Crypt cell hyperplasia — — — — — — —
Day 91
Duodenum








Apoptosis — — — — — þ (3/10) þ (4/10)
a





Histiocytic inﬁltration in the villous
lamina propria






Multinucleated syncytia in the villous
lamina propria
— — — — — p (2/10) p (4/10)
Jejunum








Apoptosis — — — — — — þ (2/10)





Histiocytic inﬁltration in the villous
lamina propria






Multinucleated syncytia in the villous
lamina propria
— — — — — — p (1/10)
Note. þ, minimal; þþ, mild; p, present; —, 0/5 or 0/10. Histopathological grading—villous cytoplasmic vacuolization: minimal ¼ cytoplasmic vacuolization of
< 25% of the villous epithelium, mild ¼ cytoplasmic vacuolization of   25% and < 50% of the villous epithelium; villous atrophy: minimal ¼ < 25% reduction of
the villous length, mild ¼ 25 and < 50% reduction of villous length; apoptosis: minimal ¼ < 5 apoptotic cells per 3400 ﬁeld, mild ¼ 5 and < 10 apoptotic
cells per 3400 ﬁeld; crypt cell hyperplasia: minimal ¼ > 1 and   2 times the normal crypt depth, mild ¼ > 2 and   3 times the normal crypt depth; histiocytic
inﬁltration in the villous lamina propria: minimal ¼ a few macrophages in fewer than half of the villi, mild ¼ macrophages in the villi which were readily
discernible at 310 and present in   50% and < 75% of the villi.
aSigniﬁcantly different (p   0.05) from control by Fisher’s exact test (note: þ and þþ were combined for statistical tests).
MODE OF ACTION OF ORAL TOXICITY OF Cr(VI) 63respectively. Finally, multinucleated syncytia in the villous
lamina propria were present in the jejunum of one mouse
exposed to 520 mg/l SDD (Fig. 1F).
Biochemical Evaluations
GSH and GSSG on day 8. In cells, the abundant levels of
low-molecular weight reducing agents such as GSH, cysteine,
and ascorbate are thought to be important for reducing Cr(VI)
to Cr(III) (Zhitkovich, 2005). Glutathione is estimated to be
present in many cells at 1–10mM (Schafer and Buettner, 2001)
and is therefore expected to play a major role in Cr(VI)
reduction. Because the ratio of GSH/GSSG is a key indicator of
cellular redox status (Meister and Anderson, 1983; Moriarty-
Craige and Jones, 2004; Schafer and Buettner, 2001), the GSH/
GSSG ratio was examined in several portions of the alimentary
canal. Table 3 shows the effects of Cr(VI) on the levels of GSH
and GSSG in the oral, duodenal, and jejunal epithelia, as well
as in the plasma on day 8.
In the oral epithelium, there was a signiﬁcant (p   0.05)
increase in GSSG relative to control at 520 mg/l SDD and a
signiﬁcant decrease in the GSH/GSSG ratio at   170 mg/l
SDD. In the duodenum, there was a signiﬁcant (p   0.05)
increase in GSSG and a signiﬁcant decrease in the GSH/GSSG
ratio, both starting at 60 mg/l SDD. The DE was signiﬁcantly
(p   0.05) increased relative to control at   170 mg/l SDD,
meaning a decrease in redox potential. In the jejunum, there
was a signiﬁcant decrease in GSH and an increase in DE
relative to control at   170 mg/l SDD. Figure 2 depicts the
changes in the GSH/GSSG ratio in the duodenum and jejunum
after 7 days of exposure to SDD. In the plasma, there were
signiﬁcant increases in both GSH and GSSG starting at 60 and
170 mg/l SDD, respectively; however, there were no statis-
tically signiﬁcant changes in the GSH/GSSG ratio or redox
potential (Table 3).
Overall, the data at day 8 indicate an apparent oxidative
stress response in the duodenum and, to a lesser extent, the
jejunum. The changes in the plasma indicate a potential
systemic oxidative stress response at the higher drinking water
concentrations.
GSH and GSSG on day 91. Measures of GSH, GSSG, and
redox potential after 90 days of exposure to Cr(VI) in drinking
water are shown in Table 4. Changes in the oral mucosa were
generally sporadic and did not demonstrate a clear dose-
response trend. As examples, GSH levels were signiﬁcantly
(p < 0.05) elevated at 60 mg/l SDD only, and GSSG levels
were signiﬁcantly (p < 0.01) elevated at 14 and 60 mg/l SDD
but not at higher concentrations. The GSH/GSSG ratio was
signiﬁcantly decreased (p < 0.05) at a single concentration,
14 mg/l SDD. Overall, there were no consistent changes in
glutathione parameters in the oral mucosa following 90 days of
exposure.
In the duodenum, statistically signiﬁcant (p   0.05) alter-
ations in GSH, GSSG, and the GSH/GSSG ratio were observed
at   14 mg/l SDD (Table 4). Like the duodenum, signiﬁcant
(p   0.05) increases in GSSG and decreases in the GSH/GSSG
ratio were observed at   14 mg/l SDD. Unlike the duodenum,
however, GSH levels were signiﬁcantly (p   0.05) decreased,
beginning at 60 mg/l SDD. Notably, there were no signiﬁcant
changes in any parameter in the more distal ileum. Figure 2
depicts the changes in the GSH/GSSG ratio in the duodenum
and jejunum after 90 days of exposure to SDD. Interestingly,
the effects of SDD on the GSH/GSSG ratio in the duodenum
did not appear to worsen with prolonged exposure (Fig. 2A).
In contrast, the GSH/GSSG ratio in the jejunum, which was
unaffected after 7 days of exposure (Fig. 2B), was
signiﬁcantly decreased after 90 days of exposure at concen-
trations   14 mg/l SDD.
TABLE 3






(nmol/mg) GSH/GSSG DE (mV)
a
Average SEM Average SEM Average SEM Average SEM
Oral mucosa
0 43.23 2.47 4.40 0.22 9.92 0.73  206.97 1.62
0.3 45.12 5.07 5.12 0.52 8.82 0.60  205.68 2.35
4 44.75 1.84 4.53 0.25 9.97 0.56  207.60 1.12
14 47.02 5.41 5.37 0.62 8.77 0.38  206.24 1.87
60 43.17 5.13 4.90 0.56 8.79 0.15  205.06 2.06
170 46.34 5.63 5.67 0.80 8.26
b 0.19  205.29 1.35
520 46.38 4.57 5.88
b 0.46 7.88
c 0.32  204.78 1.59
Duodenum
0 16.77 1.26 0.24 0.03 71.33 5.15  220.58 1.36
0.3 17.57 1.25 0.30 0.03 59.99 6.85  218.77 2.03
4 16.99 0.73 0.30 0.01 57.33 0.49  218.11 0.56
14 16.75 0.94 0.31 0.01 53.41 2.69  216.86 1.44
60 17.61 1.08 0.36
b 0.01 48.47
b 2.00  216.24 1.36
170 18.92 1.49 0.43
c 0.01 44.28
c 2.72  215.89
b 1.77
520 19.98 1.32 0.48
c 0.02 41.23
c 1.86  215.75
b 1.37
Jejunum
0 15.30 0.74 0.34 0.02 45.29 2.11  213.49 1.08
0.3 14.14 0.95 0.37 0.01 38.43 1.68  210.20 1.39
4 13.63 0.48 0.33 0.02 41.12 1.66  210.70 0.58
14 12.09 0.36 0.36 0.02 34.51
d 2.30  206.68 1.05
60 14.25 0.99 0.32 0.01 45.51 5.25  212.28 2.29
170 11.47
c 0.23 0.29 0.01 40.37 1.86  208.15
c 0.71
520 12.79
b 0.45 0.33 0.01 38.72 1.54  209.05
b 0.98
Plasma GSH (lM) GSSG (lM)
0 25.45 0.74 3.59 0.35 7.34 0.65  137.40 1.26
0.3 24.86 0.55 4.18 0.27 6.05 0.46  134.59 1.17
4 27.69 1.53 4.20 0.33 6.84 0.92  137.35 2.17
14 26.91 1.45 4.04 0.32 6.92 0.83  137.10 2.44
60 32.45
c 1.37 4.18 0.23 7.93 0.81  141.62 1.80
170 30.41
b 1.09 4.85
b 0.23 6.35 0.45  137.90 1.46
520 31.46
b 1.82 5.07
c 0.23 6.28 0.53  138.12 1.84
aSee ‘‘MATERIALS AND METHODS’’ for calculation.
bStatistically signiﬁcant from control by Shirley’s tests (p < 0.05).
cStatistically signiﬁcant from control by Shirley’s tests (p < 0.01).
dStatistically signiﬁcant from control by Dunn’s tests (p < 0.01).
64 THOMPSON ET AL.In the plasma, signiﬁcant (p   0.05) increases in GSSG and
GSH were observed starting at 14 and 60 mg/l SDD, respec-
tively, and signiﬁcant (p   0.01) decreases in the GSH/GSSG
ratio were observed at   170 mg/l SDD (Table 4). Overall, the
plasma data indicate that following 90 days of exposure to
Cr(VI) in drinking water, there may be systemic changes con-
sistent with an oxidative stress response albeit without any
apparent effect on the plasma redox potential.
Protein carbonyl on day 91. To further examine the effects
of SDD exposure in the duodenum, protein oxidation was
measured at day 91. A statistically signiﬁcant increase in
protein carbonyls was observed at 4 mg/l SDD. The mean
values were generally elevated in the higher treatment groups;
however, the values were not statistically different from control
animals (Fig. 2 inset).
8-OHdG on day 91. In order to examine whether the
oxidative responses in the duodenum also resulted in oxidative
DNA damage, 8-OHdG content was analyzed after 90 days of
exposure. Relative to control, there were no statistically
signiﬁcant increases in 8-OHdG in the duodenum (or oral
mucosa) at any concentration (Supplementary Fig. S3).
Cytokine and chemokine analyses on day 91. Considering
the oxidative and pathological effects (particularly histiocytic
inﬁltration) observed in the duodenum, it is conceivable that
Cr(VI) might induce inﬂammatory responses either systemically
or within the target tissues. To assess this, a multiplex of 22
cytokines and chemokines were measured in the plasma,
duodenum, and oral mucosa on day 91. For all three tissues,
the data were non-normal and exhibited heterogeneous variance.
In the serum, few cytokines exhibited signiﬁcant changes from
untreated animals. In the oral mucosa, signiﬁcant differences from
control animals were generally limited to the highest treatment
dose. In the duodenum, several cytokines were signiﬁcantly
altered—generally beginning at 60 mg/l SDD. Interestingly, the
cytokines changes in the duodenum were inversely related to
SDD concentration. The variability in the data generally obscured
visual dose-response effects; however, results for TNFa and
IL-1b exhibited clear dose-dependent trends (Fig. 3).
Clinical Chemistry
Cr(VI) exposure was previously shown to induce mild
microcytic hypochromic anemia in both rats and mice (NTP,
2008). Therefore, iron status was assessed in the serum and
bone marrow following 90 days of exposure to Cr(VI). There
were no clearly discernible effects of Cr(VI) on iron stores in
the bone marrow or circulating iron, ferritin, or transferrin
(Supplementary Table S3).
Tissue Concentrations of Total Chromium
Total chromium levels were measured in the oral cavity,
glandular stomach, and small intestine following 90 days of
exposure to Cr(VI) in drinking water (Fig. 4). Signiﬁcant
(p   0.05) increases in chromium were observed at   60 mg/l
SDD in the oral cavity, glandular stomach, jejunum, and ileum.
In the duodenum, signiﬁcant (p   0.05) increases in total
chromium were observed at   14 mg/l SDD. Notably, the
concentrations of total chromium observed in the duodenum
starting at 60 mg/l SDD were substantially greater than the
levels measured in any of the other tissues at all SDD
concentrations. It should be noted that the total chromium level
in the jejunum, which is 2–3 times longer than the duodenum,
represent an average over the entire length of the tissue. As
shown in the Figure 4 inset, analysis of total chromium in
scraped epithelial cells from the duodenum and proximal
jejunum of animals exposed to 14 or 60 mg/l SDD were
similar; this is likely the case in all treatment groups. Thus, the
lower chromium levels measured in the entire jejunum suggest
that chromium levels in the distal portion of the jejunum are
low and more similar to the levels measured in the ileum.
DISCUSSION
This study was designed to investigate the MOA for the
intestinaltumorsobservedinmicefollowingchronicexposureto
Cr(VI) in drinking water. As part of a larger set of Cr(VI) MOA
studies outlined in Table 1, the results presented herein are also
intended to serve as a phenotypic anchor to toxicogenomic
FIG. 2. Measures of GSH/GSSG ratio in the duodenum (A) and jejunum (B) after 7 and 90 days of exposure to SDD. Data plotted are mean and SEM (n ¼ 5
animals), which are also reported in Tables 3 and 4. Inset: mean protein carbonyl content in duodenum at day 91.
MODE OF ACTION OF ORAL TOXICITY OF Cr(VI) 65studies being conducted as part of the project. Although the
focus herein is on the mouse small intestine, the oral mucosa
was also studied for future comparisons with a 90-day rat
study. Rats were previously shown to develop oral cavity
tumors (but not intestinal tumors) following oral exposure to
Cr(VI)(NTP,2008).ConsistentwiththepreviousNTPstudies
(NTP, 2007, 2008), there were no histopathologicallesions in
the mouse oral mucosa. In addition, at day 91, there were no
apparent treatment-related changes in GSH, GSSG, or 8-




In the small intestine, signiﬁcant decreases in the GSH/
GSSG ratio occurred in the duodenum at day 8 starting at
60 mg/l SDD and signiﬁcant changes in redox potential (DE)
occurred at   170 mg/l SDD. Histopathological lesions observed
included cytoplasmic vacuolization (  170 mg/l SDD), atrophy
(520 mg/l SDD), and crypt hyperplasia (520 mg/l SDD). Notably,
these results suggest that exposure to high concentrations of
Cr(VI) induced a fairly rapid onset of compensatory cell prolif-
eration. In the jejunum, there was a signiﬁcant decrease in GSH
levels and increase in DE at   170 mg/l SDD; however, there
were no signiﬁcant changes in the GSH/GSSG ratio.
After 90 days of exposure to Cr(VI), similar histopathological
lesions were observed in the duodenum as at day 8 but occurred
at lower concentrations: cytoplasmic vacuolization occurred
at   60 mg/l SDD, whereas atrophy, apoptosis, and crypt
hyperplasia occurred at   170 mg/l SDD. The incidence and
severity of microscopic lesions increased at 170 and 520 mg/l
SDD. Statistically signiﬁcant changes in GSH, GSSG, and the
FIG. 3. Measures of TNFa (A) and IL-1b (B) in the duodenum after 90
days of exposure to SDD. Data were normalized to protein content. Whiskers
represent the 10th and 90th percentiles. *p < 0.05, **p < 0.01 compared with
control group by Shirley’s test.
TABLE 4






(nmol/mg) GSH/GSSG DE (mV)
a
Average SEM Average SEM Average SEM Average SEM
Oral mucosa
0 39.12 2.02 3.91 0.11 10.05 0.61  205.86 1.48
0.3 40.35 1.03 4.25 0.11 9.52 0.30  205.69 0.69
4 43.93 2.77 4.49 0.16 9.92 0.98  207.08 2.00
14 43.08 1.17 5.38
b 0.22 8.04
c 0.26  204.30 0.58
60 46.01
c 1.87 5.42
b 0.38 8.62 0.58  205.98 1.21
170 40.54 1.42 4.68 0.26 8.74 0.44  204.55 0.97
520 37.71 1.19 4.13 0.16 9.15 0.28  204.25 0.66
Duodenum
0 18.20 1.00 0.25 0.02 72.29 5.58  221.94 1.52
0.3 20.06 1.17 0.29 0.02 69.58 5.41  222.69 1.80
















e 2.19  218.65 1.14
Jejunum
0 17.95 0.55 0.33 0.02 56.21 5.28  218.35 1.67
0.3 18.00 1.19 0.33 0.03 55.67 3.41  218.32 1.20
4 16.81 0.53 0.37 0.01 45.08 2.15  214.72 0.98
14 15.97 0.71 0.42
d 0.04 39.09















e 2.30  203.47
e 2.04
Ileum
0 15.85 0.88 0.33 0.03 49.67 3.15  215.13 0.89
0.3 16.98 0.97 0.35 0.02 48.52 2.37  215.76 1.34
4 16.78 1.22 0.37 0.06 47.00 3.61  215.02 0.84
14 16.66 1.02 0.32 0.02 51.85 2.99  216.37 1.34
60 16.40 0.70 0.37 0.04 45.85 2.58  214.56 0.42
170 16.17 1.48 0.34 0.03 48.03 2.59  214.82 1.49
520 17.18 1.35 0.32 0.03 55.30 2.57  217.61 0.93
Plasma
f GSH (lM) GSSG (lM)
0 35.23 2.03 5.98 0.47 6.05 0.61  139.06 1.83
0.3 39.63 2.98 6.73 0.17 5.91 0.45  140.35 2.02
4 37.96 3.31 8.77 0.55 4.46 0.60  135.55 3.22
14 44.21 2.94 11.84
e 1.41 4.04 0.69  136.13 3.03
60 50.13
e 1.81 10.02








e 0.32  135.41 2.21
aSee ‘‘MATERIALS AND METHODS’’ for calculation.
bStatistically signiﬁcant from control by Dunn’s tests (p < 0.01).
cStatistically signiﬁcant from control by Dunn’s tests (p < 0.05).
dStatistically signiﬁcant from control by Shirley’s tests (p < 0.05).
eStatistically signiﬁcant from control by Shirley’s tests (p < 0.01).
fn ¼ 4 for plasma GSH, GSH/GSSG, and DE.
66 THOMPSON ET AL.GSH/GSSG ratio were observed at   14 mg/l SDD, and these
effects were somewhat more pronounced at 170 and 520 mg/l
SDD. These data suggest that biochemical changes in GSH and
GSSG are sensitive indicators of redox status, and these changes
serve as more sensitive indicators of exposure and/or toxicity
than histopathology. Despite clear dose-dependent changes in
oxidative status, protein carbonyl levels (measures of protein
oxidation) were only modestly elevated and generally exhibited
an all-or-nothing response (Fig. 2). Review of literature where
protein carbonyl content has been measured generally indicates
such phenomena; for example, treatment of cells with 0.1–1mM
peroxide was shown to result in only modest increases in protein
carbonyl content (see Wang et al.,2 0 0 3 ).
Oxidative DNA damage (as measured by 8-OHdG) was not
signiﬁcantly increased in any treatment group relative to control
mice. This ﬁnding is consistent with a study that reported
no increases in 8-OHdG (using
32P post labeling) in mucosal
scrapings from the duodenum and stomach of mice exposed to
14 or 57 mg/l SDD in drinking water for 9 months (De Flora
et al.,2 0 0 8 ). In contrast, previous studies involving intratracheal
instillation of SDD for 3 days resulted in an increase in 8-OHdG
in the rodent lung (Izzotti et al.,1 9 9 8 ). The basis for the
8-OHdG differences observed in the lung and intestine is not
well understood at this time and requires further investigation.
Nonetheless, the lack of increase in 8-OHdG is not novel, as
studies with peroxisome proliferators have shown that oxidative
stress can be induced without detectible increases in DNA
damage (including 8-OHdG), and that such exposure can lead to
elevated expression of genes related to DNA repair (Rusyn
et al.,2 0 0 4 ). Thus, it is conceivable that 8-OHdG lesions were
repaired or that the oxidative stress was not sufﬁcient to induce
measurable increases in 8-OHdG. The toxicogenomics data from
the mice in this study (Table 1) may ultimately provide insights
as to whether exposure to Cr(VI) resulted in changes in genes
related to repair of oxidative DNA damage.
Although there was histiocytic inﬁltration in the small
intestine, cytokines and chemokines were not elevated
systemically or locally in the duodenum. Interestingly, the
changes in cytokines and chemokines that were observed in the
duodenum were all inversely related to the SDD concentration.
Data in Figure 3 suggest that Cr(VI) reduced the duodenal
levels of TNFa and IL-1b in a dose-dependent manner, both of
which are regulated by NF-jB( Rahman and MacNee, 2000;
Roberts et al., 2009). Decreases in TNFa and IL-1b are also
apparent at the transcript level (Kopec et al., Thompson, Kim,
Forgacs, Harris, O’Brien, Proctor, Burkhalter, Haws, and
Zacharewski, in preparation). Previous studies have shown that
treatment of cells with Cr(VI) ameliorates TNFa-induced NF-
jB–driven luciferase activity in vitro—potentially due to redox-
mediatedproteinthiolmodiﬁcation(Shumillaetal.,1998,1999).
Thus, itis possible that chromium affects either TNFa or NF-jB
activity and may disrupt inﬂammatory signaling. Alternatively,
the variability and trend toward decreased cytokine levels in the
duodenum may reﬂect the complex temporal nature of in-
ﬂammatory signaling and/or an overall decrease in protein
expression levels due to toxicity.
FIG. 4. Measures of total chromium (Cr) in the oral mucosa, glandular stomach, and small intestine following 90 days of exposure to SDD in drinking water.
Note that all values in control and 0.3 mg/l SDD groups are estimates and were either below the method detection limit (MDL) or above the MDL but below the
method reporting limit (MRL). The MDL and MRL for the intestinal samples were 0.02 and 0.15 lg/g, respectively, whereas the MDL and MRL for oral cavity tissue
are about 10-fold higher. Data plotted are mean and SEM. All tissues exhibited signiﬁcant (p < 0.001) trend for increased Cr levels. Bars under the capped line were all
signiﬁcantly increased relative to their respective control tissues by Shirley’s test (p   0.05). *Signiﬁcantly different from control by Shirley’s test (p < 0.05). The inset
shows a comparison of Cr in scraped epithelial cells from the duodenum (D) and proximal portion of the jejunum (J) in the 14 and 60 mg/l SDD treatment groups.
Data represent mean and SEM.
MODE OF ACTION OF ORAL TOXICITY OF Cr(VI) 67The histological lesions and changes in biochemical
parameters in the duodenum are consistent with the tissue
chromium levels. As shown in Table 5, signiﬁcant increases in
chromium were detected in the duodenum at   14 mg/l SDD,
which coincided with signiﬁcant decreases in the GSH/GSSG
ratio. At 60 mg/l SDD, histological lesions in the form of
cytoplasmic vacuolization were observed. At   170 mg/l SDD,
atrophy and apoptosis were observed in the intestinal villous,
and hyperplasia was observed in the intestinal crypt. These
ﬁndings show a clear progression of effects in the mouse
duodenum following 90 days of exposure to Cr(VI) that
includes changes in redox status (  14 mg/l SDD), oxidative
stress and cytoplasmic vacuolization (  60 mg/l SDD), and
atrophy, apoptosis, and regenerative crypt cell hyperplasia
(  170 mg/l SDD). A similar pattern is likely for the jejunum;
however, the available data do not allow for direct assessment
of this notion because, unlike the duodenum, only the most
proximal portion of the jejunum was used for biochemical
analyses, whereas the entire jejunum was used for chromium
analysis.
In the present study, GSSG levels increased in both the
duodenum and the jejunum after 90 days of exposure to Cr(VI).
This could result from general Cr(VI)-induced oxidative stress
as antioxidants such as GSH are diminished in concentration
or possibly due to intracellular reduction of Cr(VI) to Cr(V).
The latter can lead to hydrogen peroxide formation, with
subsequent catabolism by glutathione peroxidase that simulta-
neously converts GSH to GSSG (see Thompson et al., 2011).
In contrast to GSSG, GSH levels exhibited different responses
in intestinal segments: a dose-dependent increase in the
duodenum and a dose-dependent decrease in the jejunum.
GSH levels typically decrease when reactive compounds bind
to GSH and increase after activation of electrophile response
elements upstream of genes involved in GSH biosynthesis
(Franco and Cidlowski, 2009). Thus, the increase in GSH
observed in the duodenum may represent an oxidative stress
response that includes enhanced GSH synthesis. Indeed, pre-
liminary toxicogenomic analyses indicate that the glutamate-
cysteine ligase catalytic subunit (Gclc) mRNA, which codes
for the rate-limiting enzyme in GSH synthesis, is elevated at
several SDD concentrations (Kopec et al., in preparation).
Moreover, the glutathione peroxidase (Gpx1) mRNA, which
codes for the enzyme that catalyzes the GSH-dependent
detoxiﬁcation of peroxide, is elevated at   170 mg/l SDD
(Kopec et al., in preparation). Elevations in Gclc at concen-
trations where chromium was not detected in the duodenal
tissue may represent responses to extracellular thiol status as
studies suggest that intestinal cells regulate the extracellular
redox environment, and redox sensitive cell surface proteins
can inﬂuence intracellular gene expression (Dahm and Jones,
2000; Go et al., 2009; Mannery et al., 2010; Moriarty-Craige
and Jones, 2004). A more thorough analysis of toxicogenomic
data collected from other animals in this study may provide
additional insight into the regulation of GSH and oxidative
stress in the intestinal segments and oral mucosae of both mice
and rats.
The dosimetry data in the GI tract reported herein indicate
that chromium levels are highest in the duodenum (and proximal
jejunum). Notably, none of the other tissues exhibited chromium
levels as high as those observed in the duodenum at SDD
concentrations that were reported to be carcinogenic in the NTP
(2008) 2-year bioassay. Interestingly, chromium levels in the
glandular stomach were much lower than in the proximal small
intestine. The higher chromium level in the proximal small
intestine relative to the stomach is likely related to the structure
and function of the small intestine, which is designed for nutrient
absorption. These dosimetry data may explain the absence of
gastric tumors in mice in the NTP (2008) study.
Figure 5 shows the duodenal chromium tissue levels as a
function of the concentration of Cr(VI) in SDD-treated drinking
water. The effects reported herein occurred at tissue levels much
greater than levels which result from consumption of chromium
in the municipal tap water, which was 10
 4 mg/l Cr(VI) for the
control animals. Moreover, SDD concentrations   60 mg/l were
TABLE 5
Summary of Signiﬁcant Biochemical and Pathological Findings
at Day 91 in the Mouse Duodenum
Endpoint
SDD, mg/l
0.3 4 14 60 170 520
Tissue Cr — — [[[ [
GSH/GSSG — — YYY Y
Vacuolization — — — [[ [
Atrophy/apoptosis — — — — [[
Crypt cell proliferation — — — — [[
FIG. 5. Duodenal chromium levels after 90 days of exposure plotted in
terms of Cr(VI) (not SDD). The tap water used to treat control animals contains
trace levels of Cr(VI), measured in this study at approximately 0.098 lg/l total
Cr (including Cr(VI)). The lowest treatment concentration in the study is
equivalent to the current MCL, 100 lg/l total Cr. Tissue levels at the MCL are
nearly 1000-fold lower than those that resulted in intestinal tumors in
concurrent control animals in the 2-year NTP bioassay. Data plotted are mean
and SEM.
68 THOMPSON ET AL.bright yellow (see Supplementary Fig. S3) and concentrations
  170 mg/l were associated with reduced water intake
(Supplementary Table S2), presumably due to unpalatability.
The 0.3 mg/l SDD group in this study (0.1 mg/l Cr(VI)) is
equivalent to the current federal drinking water standard for
total chromium, and at this exposure, no appreciable increases
in tissue chromium levels or adverse effects were observed.
Notably, the chromium concentrations in the duodenum at
day 91 in the three highest treatment groups are estimated to
approach or exceed 1mM—a tissue dose that is clearly toxic
in in vitro assays. These ﬁndings suggest that the doses that
caused cancer in mice in the NTP study are associated with
cytotoxicity in target tissues. Furthermore, the increases in
plasma GSH and GSSG levels observed at the highest con-
centrations in this study might reﬂect systemic oxidative
stress and/or toxicity. In this regard, it was previously
suggested that the bodyweight decreases observed in the
NTP (2008) 2-year bioassay (similar to those in the present
study) indicate that the highest SDD concentration may have
exceeded the maximum tolerated dose (Stern, 2010).
Additional studies currently underway with tissues collected
from the mice treated in this study, including cytogenetic
analyses, measurement of chromium in genomic DNA, and
in vivo mutations, should provide additional measures of DNA
damage. Moreover, the toxicogenomic data for tissues from
this study should provide an additional and perhaps more sen-
sitive means to assess the dose-response for key events in the
MOA including oxidative responses. Finally, identical studies
are also underway in rats for the purpose of interspecies
comparisons.
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